Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma

BACKGROUND: Clinical studies implying the sunitinib multi-kinase inhibitor have led to disappointing results for breast cancer care but mostly focused on HER2-negative subtypes. Preclinical researches involving this drug mostly concern Triple Negative Breast Cancer (TNBC) murine models. Here, we exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Thézé, Benoît, Bernards, Nicholas, Beynel, Audrey, Bouet, Stephan, Kuhnast, Bertrand, Buvat, Irène, Tavitian, Bertrand, Boisgard, Raphaël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511439/
https://www.ncbi.nlm.nih.gov/pubmed/26198000
http://dx.doi.org/10.1186/s12885-015-1540-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511439/
https://www.ncbi.nlm.nih.gov/pubmed/26198000
http://dx.doi.org/10.1186/s12885-015-1540-2

Ejemplares similares